Ph.D., Senior Director, Corporate Development, Second Genome
Nadir Mahmood leads corporate development activities at Second Genome and is head of the Strategic Partnerships Group. He is responsible for establishing strategy and partnerships across the company’s portfolio of programs and overseas all intellectual property matters. Nadir was previously a scientist at Kythera Biopharmaceuticals (acquired by Allergan) where he oversaw preclinical research for the company’s lead molecule, Kybella®. He has also worked as an equity research analyst at Goldman Sachs & Co. and consulted for various start up companies in the life sciences and clean energy sectors. He has a bachelor’s degree in Biochemistry from the University of Texas at Austin and received a PhD in Cell Regulation from the University of Texas Southwestern Medical Center at Dallas. Nadir completed postdoctoral research in the Department of Chemistry at the Scripps Research Institute in La Jolla, CA.
Presentation Title and Company Description
Microbial Profiling Showcase: Transforming Human Health Through Microbiome Science
We are a clinical stage technology company with a mission to improve human health & wellness by creating a new spectrum of medicines derived from the human microbiome. Our validated proprietary technology platform allows us to harvest an unprecedented array of new bioactive molecules and probiotics from the microbiome. This opens up vast new application areas in medicine, human nutrition, wellness & longevity.